Senard J M, Colomes M, Rostin M, Clanet M, Montastruc J L
Service de Pharmacologie Médicale et Clinique, INSERM U317, Centre Hospitalier Universitaire, Faculté de Médecine, Toulouse.
Therapie. 1990 Mar-Apr;45(2):157-9.
The ability of flunarizine in inducing or worsening extrapyramidal symptoms is well documented. The relation with age or dose of such symptoms as their clinical characteristics remain controversial. We report 6 cases of extrapyramidal syndromes induced by flunarizine in five women and one man (mean age 71.5 +/- 5 years). The daily dose was 10 mg in five cases (as recommended by the marketing laboratory) and 20 mg in one patient. These observations allow to discuss the dose-dependent occurrence of this adverse reaction. In only three cases the reason for treatment was compatible with the official french indication. These side effects appeared after 7.0 +/- 1.6 months and disappeared after 2.2 +/- 0.5 months respectively. Flunarizine-induced extrapyramidal symptoms are mainly characterized by tremor (which was the main symptom in 4 cases and the only one in 2 cases).
氟桂利嗪诱发或加重锥体外系症状的能力已有充分文献记载。其与年龄、剂量的关系以及这些症状的临床特征仍存在争议。我们报告6例由氟桂利嗪诱发的锥体外系综合征病例，其中5名女性，1名男性（平均年龄71.5±5岁）。5例患者的日剂量为10mg（按照药品上市许可持有人推荐），1例患者为20mg。这些观察结果有助于讨论这种不良反应的剂量依赖性发生情况。仅3例患者的治疗原因符合法国官方适应证。这些副作用分别在7.0±1.6个月后出现，2.2±0.5个月后消失。氟桂利嗪诱发的锥体外系症状主要表现为震颤（4例以震颤为主要症状，2例仅表现为震颤）。
